LB-1904

N/A

Report date: 2022/08/09 15:34:41

Base Information

Drug NameLB-1904

Drug Alias NameLB-1904

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CLDN18

TargetsClaudin-18 splice variant 2

Therapy Area/IndicationsStomach Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesNanjing Legend Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesNanjing Legend Biotechnology Co Ltd

Inactive CompaniesN/A

Active IndicationsStomach Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A